BiotechTube

Tibulizumab Dose A + Tibulizumab Dose B

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa (HS)

Conditions

Hidradenitis Suppurativa (HS)

Trial Timeline

May 16, 2025 → Apr 1, 2027

NCT ID
NCT06993610

About Tibulizumab Dose A + Tibulizumab Dose B

Tibulizumab Dose A + Tibulizumab Dose B is a phase 2 stage product being developed by Zura Bio for Hidradenitis Suppurativa (HS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06993610. Target conditions include Hidradenitis Suppurativa (HS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06993610Phase 2Recruiting

Competing Products

20 competing products in Hidradenitis Suppurativa (HS)

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
LutikizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
Lutikizumab + PlaceboAbbViePhase 2
52
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
MEDI8968 + SalineAstraZenecaPhase 2
52

Other Products from Zura Bio

TibulizumabPhase 2
44